Skip to main content

Approaches Targeting KV10.1 Open a Novel Window for Cancer Diagnosis and Therapy

Buy Article:

$55.00 plus tax (Refund Policy)

KV10.1 has recently become generally accepted as a promising cancer target, as it is ectopically expressed in the majority of solid tumors. Due to its cell-surface accessibility, KV10.1 has a strong potential for tumor treatment and diagnosis. Given that its mode of action is likely independent of conventional cancer pathways such as tyrosine kinases, KV10.1 opens a novel window for treating cancer. In this review we will give an overview of the current status of data linking KV10.1 to cancer, and propose techniques that could exploit KV10.1's properties for the management of cancer

No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: ADEPT; KCNH1; KV10.1; astemizole; cancer diagnosis; cancer prognosis; eag1; ether a go-go; imipramine; immunotargeted therapy; immunotherapy; potassium channel; tumor therapy

Document Type: Research Article

Publication date: 2012-02-01

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more